💥 MIBC is no longer surgery-first—oncology is rewriting the rulebook. 🩺 Surgery & Chemo (traditional backbone) Radical cystectomy ± peri-op cisplatin chemo remains standard, but morbidity & patient fitness limit its universal application. 🧬 Immunotherapy integration Neo/adjuvant ICB now proven: • CheckMate-274 → Nivolumab improved DFS & OS • AMBASSADOR → Pembrolizumab improved DFS • NIAGARA → Durvalumab peri-op improved DFS & OS 🧪 ctDNA as MRD tool • Detectable ctDNA predicts relapse post-cystectomy • IMvigor010, TOMBOLA, MODERN exploring ctDNA-guided escalation/de-escalation 🚦 → Personalised systemic therapy decisions on horizon. 🎯 ADCs ICB combos • EV pembro (EV-302) revolutionised metastatic setting • Now moving peri-op in VOLGA, KEYNOTE-905, KEYNOTE-B15 → Potential to boost cure rates in cisplatin-eligible & ineligible pts. 🛡️ Bladder-sparing strategies • TURBT systemic therapy → durable CR in select pts (HCRN GU16-257, RETAIN) • Emerging risk-adapted, biomarker-driven pathways • Goal: preserve organ without compromising cure. ➡️ The next decade = convergence of powerful therapeutics precise biomarkers risk-adapted strategies. Not just longer survival-cure quality of life together. 📖 JCO 2025 Review: ascopubs.org/doi/full/10.120… @ASCO @oncoalert @uro_today @theNCI #BladderCancer #Oncology #UroOnc #Immunotherapy #CancerResearch

Phase II SunRISe-1: TAR-200 (slow drug-releasing system for gemcitabine) achieved CR in 82% of pts with BCG-unresponsive high-risk NMIBC @JCO_ASCO 🩺@siadaneshmand ❕#FDA priority review granted ascopost.com/news/august-202…

Heal with steel in cN UTUC. 🩹🩹 🇹🇼 Nationwide cohort (n=288): RNU ↓ UTUC-specific mortality 69%→36%, 5-yr CSS 0%→39% vs. no surgery. Surgery still matters N disease #UroOnc #UTUC nature.com/articles/s41598-0…

💫🌟📢 The impact of radical cystectomy (RC) on sexual health & QoL🌟💫 Presenter: @PignotG | Moderator: @CLebacle #BLADDR24 @OncoAlert @mirrorsmed 🔍 Key Points: 🟠RC impacts sexual function significantly. Yet, 41.2% of urologists avoid discussing sexual outcomes with patients. 🟠Gender gap: Women are underserved in sexual health post-RC, highlighting the need for PROMS to guide improvements. 🟠Functional recovery: Sexual-sparing strategies lead to better sexual function & urinary continence, boosting QoL. 🟠Multimodal management (incl. sex therapy, physical treatments) enhances post-op outcomes for both genders. 🛠️ Call to Action: Incorporate sexual outcomes as a surgical endpoint & empower patients with comprehensive pre-op counseling! @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #BladderCancer #UroOncology #QoL #PatientCare 🧑‍⚕️👩‍⚕️

💡 Highlights from #BLADDR24: Translating Data into Practice 🚨 Moderators: @CLebacle & Fred Witjes 🔥 Practical insights into intravesical instillation for bladder cancer: @OncoAlert @mirrorsmed Efficacy Tips: Limit voiding before therapy 🚫💧 & drink fluids after 💦. Toxicity Risks: Hygiene matters! Men should void sitting 👨‍⚕️🚻. Post-op timing matters for MMC—best on surgery day ⏰🔬. 2023 Guidelines: Continuous saline irrigation 🌊 recommended for chemo-ineligible. New tools like TAR-200 & GemRIS showing promise 🌟. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #OncoTwitter #UroOncology #BladderCancer

Fantastic talks on practical surgical questions on DAY 2 of #BLADDR24 - Practical aspects of intravesical instillation by Fred Witjes - The optimal TURBT by Ben-Max de Ruiter - The impact of RC on sexual function/experience by @PignotG Moderation: @CLebacle @OncoAlert

So fun to debate my friend & colleague @b_szabados on role of ctDNA in #bladdercancer citing data from TOMBOLA IMvigor011, etc. Great moderation by @DanieleRaggi83 @tompowles1 @Uromigos @AndreaNecchi @MattGalsky @JoshMeeks @achoud72 @KilianGust @OncoAlert @mirrorsmed #BLADDR24

Day One of #BLADDR24 Presenter: Dr Cédric Lebâcle Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? PRO and CON PRO: The debate on whether we are ready to de-intensify treatment and surveillance in low-grade non-muscle invasive bladder cancer (NMIBC) sees the "pro" side arguing that an adapted de-intensification strategy offers several benefits. These include minimizing the risks and side effects of interventions, reducing patient anxiety, and easing the treatment burden, all while ensuring safe and effective care. From a global perspective, this approach can help decrease unnecessary procedures in low-risk NMIBC patients without compromising cancer control, maintaining oncological outcomes while improving overall patient quality of life. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @nataliagandur @yekeduz_emre @bavilima @niklas_kluemper @DrYukselUrun @mirrorsmed @bkonety @evacomperat @Achard_Verane @daandm @mdesantis234 @KilianGust @bkonety @CLebacle @LAUrology_NL @Renate_Pichler @DanieleRaggi83 @CelenaBergdahl @bm_deruiter Still time to Register: buff.ly/3Z4aEt3

Big AI discovered a new structural class of antibiotics! The last one took 38 years with multiple compounds effective vs methicillin-resistant Staph aureus, without toxicity. Article: nature.com/articles/s41586-0…

A big day for bladder ca patients @US_FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn

Des applis de suivi de malades du cancer remboursées, un « tournant » dans la prise en charge whatsupdoc-lemag.fr/article/…

#CFU2023 session TVIM : analyse PMSI sur > 5000 cystectomies en France : la cystectomie par voie robot-assistée permet de diminuer la durée moyenne de séjour (-2 j) et le coût moyen du séjour (-1600e). Encore un argument supplémentaire pour privilégier cette voie d'abord !